Mga Batayang Estadistika
| LEI | 529900AY8VOOQBKJ0O70 |
| CIK | 1347178 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Vanda Pharmaceuticals Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| July 31, 2025 |
, by and between Square 54 Office Owner LLC and the registrant Exhibit 10.1 AMENDMENT NO. 7 TO LEASE THIS AMENDMENT NO. 7 TO LEASE (“Amendment No. 7”) is made as of June 24, 2025 (“Effective Date”), by and between SQUARE 54 OFFICE OWNER LLC, a Delaware limited liability company (“Landlord”), and VANDA PHARMACEUTICALS INC., a Delaware corporation (“Tenant”). WITNESSETH: WHEREAS, by Lease dated as of July 25, 2011 (the “Initial Lease”), as amended by that Amend |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commissio |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| July 31, 2025 |
Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results Exhibit 99.1 Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results •Fanapt® Q2 2025 net product sales increased by 27% to $29.3 million compared to Q2 2024 •BysantiTM (milsaperidone) NDA for bipolar I disorder and schizophrenia accepted for filing; PDUFA target action date of February 21, 2026 •Tradipitant NDA for motion sickness accepted for filing; PDUFA target action date of Decem |
|
| June 5, 2025 |
Exhibit 10.1 VANDA PHARMACEUTICALS INC. 2016 EQUITY INCENTIVE PLAN (AMENDED AND RESTATED EFFECTIVE AS OF JUNE 11, 2020) TABLE OF CONTENTS Page ARTICLE 1. INTRODUCTION A-1 ARTICLE 2. ADMINISTRATION A-1 2.1 Committee Composition A-1 2.2 Committee Responsibilities A-1 2.3 Committee for Non-Officer Grants A-1 ARTICLE 3. SHARES AVAILABLE FOR GRANTS A-1 3.1 Basic Limitation A-1 3.2 Shares Returned to Re |
|
| June 5, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Vanda Pharmaceuticals Inc. |
|
| June 5, 2025 |
As filed with the Securities and Exchange Commission on June 5, 2025 As filed with the Securities and Exchange Commission on June 5, 2025 Registration No. |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commission |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| May 8, 2025 |
Exhibit 10.1 Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan: Notice of Restricted Stock Unit Award You have been granted units representing shares of Common Stock of Vanda Pharmaceuticals Inc. (the “Company”) on the following terms: Name of Recipient: [Name] Total Number of Units Granted: [Number of Shares] Date of Grant: [Date] Vesting Schedule: 25% of the units subjec |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commission |
|
| May 7, 2025 |
Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results Exhibit 99.1 Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results • Fanapt® Q1 2025 total prescriptions (TRx) increased 14% compared to Q1 2024 •Fanapt® Q1 2025 new to brand prescriptions (NBRx) increased nearly threefold compared to Q1 2024 •BysantiTM (milsaperidone) NDA for bipolar I disorder and schizophrenia accepted for filing; PDUFA target action date of February 21, 2026 •Trad |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| April 25, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permi |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 (March 14, 2025) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorpo |
|
| February 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 (February 18, 2025) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of i |
|
| February 14, 2025 |
EXHIBIT 19.1 VANDA PHARMACEUTICALS INC. POLICY MEMORANDUM CONCERNING SECURITIES TRADING (As of December 13, 2023) I.Statement of Company Policy Regarding Securities Trading A.Officers, directors and employees of Vanda Pharmaceuticals Inc. and its subsidiaries (collectively, the “Company”) who obtain material non-public information about the Company’s affairs shall maintain the confidentiality of t |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-34186 VANDA PHARMACEUTICALS INC. (Exact name of regist |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commi |
|
| February 13, 2025 |
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results Exhibit 99.1 Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results •Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023 •Q4 2024 Fanapt® net product sales of $26.6 million, +18% compared to Q4 2023 •Full year 2024 total revenues of $198.8 million, +3% compared to full year 2023 •Full year 2025 revenue expected to grow to $210 to $250 million •Psychiatry po |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2025 (January 25, 2025) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of inc |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commis |
|
| November 6, 2024 |
Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results Exhibit 99.1 Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results •Revenues for Q3 2024 were $47.7 million, an increase of 23% compared to Q3 2023 •Financial Guidance revised for Full Year 2024, raising the midpoint of revenue and cash ranges •Fanapt® launch in bipolar I disorder; new patient starts increased by over 90% in Q3 2024 as compared to Q3 2023 •Fanapt® long acting injectab |
|
| October 15, 2024 |
Exhibit 99.1 Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd. Board Has Determined That Latest Proposal Is Not in the Best Interests of the Company or Stockholders WASHINGTON, October 14, 2024 – Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (Nasdaq: VNDA) today confirmed that it received a second unsolicited, |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2024 (October 14, 2024) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of inc |
|
| October 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2024 (October 2, 2024) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incor |
|
| October 3, 2024 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF VANDA PHARMACEUTICALS INC. A DELAWARE CORPORATION (as of October 2, 2024) TABLE OF CONTENTS Article I OFFICES AND RECORDS 1 Section 1.1 Delaware Office 1 Section 1.2 Other Offices 1 Section 1.3 Books and Records 1 Article II STOCKHOLDERS 1 Section 2.1 Annual Meeting 1 Section 2.2 Special Meeting 1 Section 2.3 Place of Meeting 1 Section 2.4 Notice of Meeti |
|
| September 19, 2024 |
FDA Declines to Approve Vanda’s Marketing Application for Tradipitant in Gastroparesis Exhibit 99.1 FDA Declines to Approve Vanda’s Marketing Application for Tradipitant in Gastroparesis WASHINGTON, September 19, 2024 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its tradipitant development program. On September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Vanda’s New Drug Application (NDA) of tradipitant for the treatme |
|
| September 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2024 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Comm |
|
| August 8, 2024 |
EX-4.1 Exhibit 4.1 AMENDMENT NO. 2 TO THE RIGHTS AGREEMENT Dated as of August 7, 2024 between VANDA PHARMACEUTICALS INC. and EQUINITI TRUST COMPANY, LLC, as Rights Agent AMENDMENT NO. 2 TO THE RIGHTS AGREEMENT This Amendment No. 2 to the Rights Agreement, dated as of August 7, 2024 (this “Amendment”), is entered into by and between Vanda Pharmaceuticals Inc., a Delaware corporation (the “Company”) |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commissi |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 2) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Vanda Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 03-0491827 (State or other jurisdiction of incorporation or organization) (I.R.S. Empl |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commissio |
|
| July 31, 2024 |
Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results Exhibit 99.1 Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results •Revenues for Q2 2024 were $50.5 million, an increase of 6% compared to Q1 2024 and an increase of 10% compared to Q2 2023 •Financial Guidance reinstated for Full Year 2024 •Fanapt® approved for the acute treatment of bipolar I disorder; commercial launch initiated in Q3 2024 •PONVORY® commercial launch in multiple sc |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 (June 19, 2024) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorpora |
|
| June 20, 2024 |
Exhibit 99.1 Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders WASHINGTON, June 19, 2024 /PRNewswire/ – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Company’s Board of Directors (the “Board”), following careful review and consultation with its independent fin |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commissio |
|
| June 13, 2024 |
EX-99.1 Exhibit 99.1 Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak No Shareholder Action Required at This Time WASHINGTON, June 13, 2024 /PRNewswire/ – Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (Nasdaq: VNDA) today confirmed that it has received a revised unsolicited proposal from Future Pak, LLC (“FP”) to acquire Vanda for $8.50-$9.00 |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commission |
|
| June 6, 2024 |
EX-99.1 Exhibit 99.1 Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd. No Shareholder Action Required at This Time WASHINGTON, June 6, 2024 – Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (Nasdaq: VNDA) today confirmed that it has received an unsolicited, non-binding indication of interest from Cycle Group Holdings Ltd. |
|
| May 24, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commission |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 (May 17, 2024) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorpora |
|
| May 24, 2024 |
Exhibit 99.1 Vanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its Shareholders WASHINGTON, May 24, 2024 /PRNewswire/ - Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Company’s Board of Directors (the “Board”) carefully reviewed the revised unsolicited proposal from Future Pak, |
|
| May 21, 2024 |
As filed with the Securities and Exchange Commission on May 21, 2024 As filed with the Securities and Exchange Commission on May 21, 2024 Registration No. |
|
| May 21, 2024 |
Exhibit 10.1 VANDA PHARMACEUTICALS INC. 2016 EQUITY INCENTIVE PLAN (AMENDED AND RESTATED EFFECTIVE AS OF JUNE 11, 2020) TABLE OF CONTENTS Page ARTICLE 1. INTRODUCTION 1 ARTICLE 2. ADMINISTRATION 1 2.1 Committee Composition 1 2.2 Committee Responsibilities 1 2.3 Committee for Non-Officer Grants 1 ARTICLE 3. SHARES AVAILABLE FOR GRANTS 1 3.1 Basic Limitation 1 3.2 Shares Returned to Reserve 2 ARTICL |
|
| May 21, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Vanda Pharmaceuticals Inc. |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 (May 17, 2024) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporati |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commission |
|
| May 8, 2024 |
Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results Exhibit 99.1 Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results •Revenues for Q1 2024 were $47.5 million, an increase of 5% compared to Q4 2023 •Cash increase of $5.9 million in Q1 2024 to $394.1 million •Fanapt® approved for the acute treatment of bipolar I disorder; commercial launch expected in Q3 2024 •Milsaperidone NDA for schizophrenia and bipolar disorder expected to be subm |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commission |
|
| May 7, 2024 |
EX-99.1 Exhibit 99.1 Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak No Shareholder Action Required at This Time WASHINGTON, May 7, 2024 /PRNewsire/ – Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (Nasdaq: VNDA) today confirmed that it has received a revised unsolicited proposal from Future Pak, LLC (“Future Pak”) to acquire the Company. The |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commission |
|
| May 3, 2024 |
EX-4.1 Exhibit 4.1 AMENDMENT NO. 1 TO THE RIGHTS AGREEMENT Dated as of May 3, 2024 between VANDA PHARMACEUTICALS INC. and EQUINITI TRUST COMPANY, LLC, as Rights Agent AMENDMENT NO. 1 TO THE RIGHTS AGREEMENT This Amendment No. 1 to the Rights Agreement, dated as of May 3, 2024 (this “Amendment”), is entered into by and between Vanda Pharmaceuticals Inc., a Delaware corporation (the “Company”), and |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 1) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Vanda Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 03-0491827 (State or other jurisdiction of incorporation or organization) (I.R.S. Empl |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| April 17, 2024 |
Exhibit 4.1 RIGHTS AGREEMENT Dated as of April 17, 2024 between VANDA PHARMACEUTICALS INC. and EQUINITI TRUST COMPANY, LLC, as Rights Agent TABLE OF CONTENTS Page Section 1. Certain Definitions 1 Section 2. Appointment of Rights Agent 11 Section 3. Issuance of Rights Certificates 12 Section 4. Form of Rights Certificates 14 Section 5. Countersignature and Registration 15 Section 6. Transfer, Split |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Vanda Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 03-0491827 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification |
|
| April 17, 2024 |
Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan Exhibit 99.1 Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan WASHINGTON, April 17, 2024 – Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (Nasdaq: VNDA) today announced that its Board of Directors (the “Board”) has adopted a limited duration stockholder rights plan (the “Rights Plan”) to protect stockholder interests and maximize value for all stockholders. The Rights P |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2024 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commissi |
|
| April 17, 2024 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF DESIGNATION OF RIGHTS, PREFERENCES AND PRIVILEGES OF SERIES A JUNIOR PARTICIPATING PREFERRED STOCK OF VANDA PHARMACEUTICALS INC. Pursuant to Section 151 of the General Corporation Law of the State of Delaware Vanda Pharmaceuticals Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”) |
|
| April 17, 2024 |
Exhibit 99.2 Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak Board Determined Unsolicited Takeover Proposals Significantly Undervalue the Company No Shareholder Action Required at This Time WASHINGTON, April 17, 2024 – Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (Nasdaq: VNDA) today confirmed that, since March 2024, it received several unsolicit |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2024 (April 2, 2024) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorpora |
|
| April 3, 2024 |
Exhibit 99.1 Vanda Pharmaceuticals’ Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder Fanapt® Treatment is Now Available to Adult Patients for the Acute Treatment of Manic or Mixed Episodes Associated with Bipolar I Disorder Approval Represents Significant Novel Indication for Vanda’s Fanapt® Franchise WASHINGTON, April 2, 2024 – Vanda Pharmaceuticals I |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 (March 6, 2024) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorpora |
|
| March 7, 2024 |
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ EX-99.1 Exhibit 99.1 Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia WASHINGTON, March 6, 2024 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that on March 4, 2024, it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) as part of its ongoing review of Vanda’s suppleme |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 (February 16, 2024) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of i |
|
| February 16, 2024 |
VANDA PHARMACEUTICALS INC. PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS (unaudited) EX-99.3 Exhibit 99.3 VANDA PHARMACEUTICALS INC. PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS (unaudited) On December 7, 2023, Vanda Pharmaceuticals Inc. (Vanda or the Company) entered into an Asset Purchase Agreement to acquire certain assets comprising the exclusive rights to market and sell PONVORY® within the United States (U.S.) and Canada (Ponvory or Purchased Assets) from Actelion Pharm |
|
| February 16, 2024 |
EX-99.2 Exhibit 99.2 SPECIAL PURPOSE ABBREVIATED FINANCIAL STATEMENTS ( UNAUDITED ) PONVORY® Product Line (A Product Line of Actelion Pharmaceuticals Ltd.) Statements of Assets Acquired as of October 1, 2023 (Unaudited) and January 1, 2023 Unaudited Statements of Revenues and Direct Expenses for the nine months ended October 1, 2023 and October 2, 2022 PONVORY® Product Line Special Purpose Abbrevi |
|
| February 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2023 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of in |
|
| February 16, 2024 |
EX-99.1 Exhibit 99.1 SPECIAL PURPOSE ABBREVIATED FINANCIAL STATEMENTS PONVORY® Product Line (A Product Line of Actelion Pharmaceuticals Ltd.) As of and for the Years Ended January 1, 2023 and January 2, 2022 PONVORY® Product Line Special Purpose Abbreviated Financial Statements As of and for the Years Ended January 1, 2023 and January 2, 2022 Contents Report of Independent Auditors 2 Special Purpo |
|
| February 13, 2024 |
VNDA / Vanda Pharmaceuticals Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02188-vandapharmaceuticals.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Vanda Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 921659108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box |
|
| February 9, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Vanda Pharmaceuticals Inc (Name of Issuer) Common Stock (Title of Class of Securities) 921659108 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| February 8, 2024 |
Exhibit 10.47 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT NORMALLY TREATS AS PRIVATE AND CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED “[***]”. ASSET PURCHASE AGREEMENT by and between ACTELION PHARMACEUTICALS LTD. and VANDA PHARMACEUTICALS INC. DATED AS OF DECEMBER 7, 2023 Table of Contents P |
|
| February 8, 2024 |
Exhibit 97 VANDA PHARMACEUTICALS INC. AMENDED AND RESTATED COMPENSATION CLAWBACK POLICY (As of June 8, 2023) 1.Recoupment If Vanda Pharmaceuticals Inc. (the “Company”) is required to undertake a Restatement, then the Company shall recover, reasonably promptly, all Recoverable Compensation from any Covered Person during the Applicable Period (including those Covered Persons who are not Executive Of |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-34186 VANDA PHARMACEUTICALS INC. (Exact name of regist |
|
| February 7, 2024 |
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results •Full year 2023 revenues were $192.6 million •PONVORY® acquisition completed in Q4 2023 and transition ongoing •3 FDA PDUFA target action dates in 2024 •Ended 2023 with approximately $388 million in cash and cash equivalents WASHINGTON – February 7, 2024 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA |
|
| February 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2024 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commis |
|
| February 5, 2024 |
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ Exhibit 99.1 Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia WASHINGTON, February 5, 2024 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that on February 4, 2024, it received a notification from the U.S. Food and Drug Administration (FDA) stating that as part of its ongoing review of Vanda’s supplemental Ne |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2024 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commis |
|
| December 15, 2023 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF VANDA PHARMACEUTICALS INC. A DELAWARE CORPORATION (as of December 13, 2023) TABLE OF CONTENTS Article I OFFICES AND RECORDS 1 Section 1.1 Delaware Office 1 Section 1.2 Other Offices 1 Section 1.3 Books and Records 1 Article II STOCKHOLDERS 1 Section 2.1 Annual Meeting 1 Section 2.2 Special Meeting 1 Section 2.3 Place of Meeting 1 Section 2.4 Notice |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 (December 13, 2023) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of i |
|
| December 7, 2023 |
Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY Exhibit 99.1 Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple Sclerosis WASHINGTON, December 7, 2023 –Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has acquired U.S. and Canadian rights to PONVORY® (ponesimod) from Actelion Pharmaceuticals Ltd. (Janssen), a Johnson |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2023 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commis |
|
| November 9, 2023 |
Exhibit 10.8 UK Sub-Plan to the Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan Notice of Stock Option Grant You have been granted the following option to purchase shares of the Common Stock of Vanda Pharmaceuticals Inc. (the “Company”): Name of Optionee: [Name] Total Number of Shares: [Number of Shares] Type of Option: Unapproved Option Exercise Price Per Share: $[Exerc |
|
| November 9, 2023 |
Exhibit 10.7 Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan Notice of Stock Option Grant You have been granted the following option to purchase shares of the Common Stock of Vanda Pharmaceuticals Inc. (the “Company”): Name of Optionee: [Name] Total Number of Shares: [Number of Shares] Type of Option: Nonstatutory Stock Option Exercise Price Per Share: $[Exercise Price] |
|
| November 9, 2023 |
Exhibit 10.1 Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan: Notice of Restricted Stock Unit Award You have been granted units representing shares of Common Stock of Vanda Pharmaceuticals Inc. (the “Company”) on the following terms: Name of Recipient: [Name] Total Number of Units Granted: [Number of Shares] Date of Grant: [Date] Vesting Schedule: 25% of the units subjec |
|
| November 9, 2023 |
Exhibit 10.4 UK Sub-Plan to the Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan: Notice of Restricted Stock Unit Award You have been granted units representing shares of Common Stock of Vanda Pharmaceuticals Inc. (the “Company”) on the following terms: Name of Recipient: [Name] Total Number of Units Granted: [Number of Shares] Date of Grant: [Date] Vesting Schedule: 25% |
|
| November 9, 2023 |
Exhibit 10.5 Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan Notice of Stock Option Grant You have been granted the following option to purchase shares of the Common Stock of Vanda Pharmaceuticals Inc. (the “Company”): Name of Optionee: [Name] Total Number of Shares: [Number of Shares] Type of Option: Nonstatutory Stock Option Exercise Price Per Share: $[Exercise Price] |
|
| November 9, 2023 |
Exhibit 10.2 Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan: Notice of Restricted Stock Unit Award You have been granted units representing shares of Common Stock of Vanda Pharmaceuticals Inc. (the “Company”) on the following terms: Name of Recipient: [Name] Total Number of Units Granted: [Number of Shares] Date of Grant: [Date] Vesting Schedule: 25% of the units subjec |
|
| November 9, 2023 |
Exhibit 10.3 Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan: Notice of Restricted Stock Unit Award You have been granted units representing shares of Common Stock of Vanda Pharmaceuticals Inc. (the “Company”) on the following terms: Name of Recipient: [Name] Total Number of Units Granted: [Number of Shares] Date of Grant: [Date] Vesting Schedule: [1 Year or 4 Year Vesti |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 9, 2023 |
Exhibit 10.6 Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan Notice of Stock Option Grant You have been granted the following option to purchase shares of the Common Stock of Vanda Pharmaceuticals Inc. (the “Company”): Name of Optionee: [Name] Total Number of Shares: [Number of Shares] Type of Option: Nonstatutory Stock Option Exercise Price Per Share: $[Exercise Price] |
|
| November 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commis |
|
| November 8, 2023 |
Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results Exhibit 99.1 Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results •Total revenues in the first nine months of 2023 were $147.4 million •Vanda provides update on pipeline advancements and regulatory plans WASHINGTON – November 8, 2023 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2023. “W |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2023 (August 16, 2023) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incor |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| July 27, 2023 |
Vanda Pharmaceuticals Reports Second Quarter 2023 Financial Results Exhibit 99.1 Vanda Pharmaceuticals Reports Second Quarter 2023 Financial Results •Q2 2023 total revenues were $46.1 million •Total revenues in the first six months of 2023 were $108.6 million •Vanda provides update on pipeline advancements and regulatory plans WASHINGTON – July 27, 2023 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the se |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commissio |
|
| June 8, 2023 |
Exhibit 10.1 VANDA PHARMACEUTICALS INC. 2016 EQUITY INCENTIVE PLAN (AMENDED AND RESTATED EFFECTIVE AS OF JUNE 11, 2020) TABLE OF CONTENTS Page ARTICLE 1. INTRODUCTION 1 ARTICLE 2. ADMINISTRATION 1 2.1 Committee Composition 1 2.2 Committee Responsibilities 1 2.3 Committee for Non-Officer Grants 1 ARTICLE 3. SHARES AVAILABLE FOR GRANTS 1 3.1 Basic Limitation 1 3.2 Shares Returned to Reserve 2 ARTICL |
|
| June 8, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Vanda Pharmaceuticals Inc. |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commission |
|
| June 8, 2023 |
As filed with the Securities and Exchange Commission on June 8, 2023 As filed with the Securities and Exchange Commission on June 8, 2023 Registration No. |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 (May 10, 2023) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporati |
|
| May 11, 2023 |
Vanda Pharmaceuticals Responds to Ruling in HETLIOZ EX-99.1 Exhibit 99.1 Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Appeal WASHINGTON, May 10, 2023 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today responded to the ruling in its HETLIOZ® Abbreviated New Drug Application appeal. Today a three-judge panel of the United States Court of Appeals for the Federal Circuit issued a written opinion that affirmed a December |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 3, 2023 |
As filed with the Securities and Exchange Commission on May 3, 2023 As filed with the Securities and Exchange Commission on May 3, 2023 Registration No. |
|
| May 3, 2023 |
Vanda Pharmaceuticals Reports First Quarter 2023 Financial Results Exhibit 99.1 Vanda Pharmaceuticals Reports First Quarter 2023 Financial Results •Q1 2023 total revenues were $62.5 million •Vanda provides update on three upcoming regulatory submissions WASHINGTON – May 3, 2023 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2023. “The first quarter of 2023 was busy and ch |
|
| May 3, 2023 |
Vanda Pharmaceuticals Inc. 2200 Pennsylvania Avenue NW Suite 300E Washington, DC 20037 CORRESP Vanda Pharmaceuticals Inc. 2200 Pennsylvania Avenue NW Suite 300E Washington, DC 20037 May 3, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street N.E. Washington, D.C. 20549 Attn: Cynthia Polynice Re: Vanda Pharmaceuticals Inc. Registration Statement on Form S-3 (File No. 333-269654) Dear Ms. Polynice: Pursuant to Rule 461 under the Securities Ac |
|
| May 3, 2023 |
EXHIBIT 10.2 Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan: Notice of Restricted Stock Unit Award You have been granted units representing shares of Common Stock of Vanda Pharmaceuticals Inc. (the “Company”) on the following terms: Name of Recipient: [Name] Total Number of Units Granted: [#] Date of Grant: [Date] Vesting Schedule: 25% of the units subject to this award |
|
| May 3, 2023 |
Power of Attorney of Tage Honoré EX-24.2 Exhibit 24.2 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that the undersigned whose signature appears below constitutes and appoints Mihael H. Polymeropoulos, M.D. and Kevin P. Moran, and each of them singly, his true and lawful attorney-in-fact and agent, with full power to act separately and full power of substitution and resubstitution, for him and in his name, place and stead, in |
|
| May 3, 2023 |
EXHIBIT 10.1 Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan: Notice of Restricted Stock Unit Award You have been granted units representing shares of Common Stock of Vanda Pharmaceuticals Inc. (the “Company”) on the following terms: Name of Recipient: [Name] Total Number of Units Granted: [#] Date of Grant: [Date] Vesting Schedule: 25% of the units subject to this award |
|
| May 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commission |
|
| April 24, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permi |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2023 (March 15, 2023) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorpo |
|
| March 17, 2023 |
Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors Exhibit 99.1 Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors WASHINGTON, March 17, 2023 /PRNewswire/ – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the appointment of Tage Honoré, Ph.D., D.Sc. to its Board of Directors effective March 15, 2023. Following Dr. Honoré’s appointment, Vanda’s Board of Directors is now comprised of six directors, five of who |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commissi |
|
| February 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2023 (February 16, 2023) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of i |
|
| February 14, 2023 |
EX-99.A EXHIBIT A AGREEMENT TO FILE JOINT ACQUISITION STATEMENTS AGREEMENT made this 2nd day of FEBRUARY, 2021 by and between Delaware Funds® by Macquarie listed on Annex A hereto, Macquarie Investment Management Business Trust, Macquarie Management Holdings, Inc, and the Macquarie Parties listed on Annex B hereto (collectively referred to as the “parties”). WHEREAS, the parties hereto may be deem |
|
| February 14, 2023 |
VNDA / Vanda Pharmaceuticals Inc. / MACQUARIE GROUP LTD - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Vanda Pharmaceuticals Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 921659108 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 14, 2023 |
EX-99.B Exhibit 99.B EXHIBIT B Powers of Attorney for Macquarie Group Limited and Macquarie Bank Limited incorporated by reference to 13G filings made by Macquarie Group Limited and Macquarie Bank Limited on May 25, 2021. Page 13 of 13 |
|
| February 10, 2023 |
SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Vanda Pharmaceuticals Inc (Name of Issuer) Common Stock (Title of Class of Securities) 921659108 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 9, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Fee Filing Tables Form S-3 (Form Type) Vanda Pharmaceuticals Inc. |
|
| February 9, 2023 |
As filed with the Securities and Exchange Commission on February 9, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on February 9, 2023 Registration No. |
|
| February 9, 2023 |
VNDA / Vanda Pharmaceuticals Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02161-vandapharmaceuticals.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Vanda Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 921659108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-34186 VANDA PHARMACEUTICALS INC. (Exact name of regist |
|
| February 9, 2023 |
EX-4.2 2 d439520dex42.htm EX-4.2 Exhibit 4.2 VANDA PHARMACEUTICALS INC. AND , as Trustee INDENTURE Dated as of Debt Securities Reconciliation and tie between Trust Indenture Act of 1939, as amended, and the Indenture Trust Indenture Act Section Indenture Section §310(a)(1) 6.8 (a)(2) 6.8 (b) 6.9 §312(a) 7.1 (b) 7.2 (c) 7.2 §313(a) 7.3 (b)(2) 7.3 (c) 7.3 (d) 7.3 §314(a) 7.4 (c)(1) 1.2 (c)(2) 1.2 (e |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commis |
|
| February 8, 2023 |
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results •Q4 2022 total revenues were $64.5 million •Full year 2022 revenues were $254.4 million •Vanda provides update on pipeline advancements and upcoming milestones WASHINGTON – February 8, 2023 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourt |
|
| December 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2022 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commi |
|
| December 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2022 (December 14, 2022) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of i |
|
| December 16, 2022 |
Vanda Pharmaceuticals Provides an Update to HETLIOZ EX-99.1 Exhibit 99.1 Vanda Pharmaceuticals Provides an Update to HETLIOZ® ANDA Litigation Appeal: Federal Circuit grants motion to temporarily enjoin generic launch WASHINGTON, December 16, 2022 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its appeal of the recent HETLIOZ® ANDA litigation ruling. On December 14, 2022, Vanda appealed the December 13th |
|
| December 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 (December 13, 2022) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of i |
|
| December 14, 2022 |
Vanda Pharmaceuticals Responds to Ruling in HETLIOZ EX-99.1 Exhibit 99.1 Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Litigation WASHINGTON, December 13, 2022 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today responded to the ruling in its HETLIOZ® ANDA Litigation. Vanda has brought several Hatch-Waxman lawsuits in the United States District Court for the District of Delaware against Teva Pharmaceuticals USA, Inc. |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 2, 2022 |
Vanda Pharmaceuticals Reports Third Quarter 2022 Financial Results Exhibit 99.1 Vanda Pharmaceuticals Reports Third Quarter 2022 Financial Results •Q3 2022 total revenues were $65.3 million •Total revenues in the first nine months of 2022 were $189.9 million •Vanda provides update on pipeline advancements and upcoming milestones WASHINGTON – November 2, 2022 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commis |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 3, 2022 |
Vanda Pharmaceuticals Reports Second Quarter 2022 Financial Results Exhibit 99.1 Vanda Pharmaceuticals Reports Second Quarter 2022 Financial Results ?Q2 2022 total revenues were $64.4 million ?Total revenues in the first six months of 2022 were $124.6 million ?Vanda provides update on pipeline advancements and upcoming milestones WASHINGTON ? August 3, 2022 /PRNewswire/ ? Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational r |
|
| August 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commissi |
|
| June 17, 2022 |
Exhibit 10.1 VANDA PHARMACEUTICALS INC. 2016 EQUITY INCENTIVE PLAN (AMENDED AND RESTATED EFFECTIVE AS OF JUNE 11, 2020) TABLE OF CONTENTS Page ARTICLE 1. INTRODUCTION 1 ARTICLE 2. ADMINISTRATION 1 2.1 Committee Composition 1 2.2 Committee Responsibilities 1 2.3 Committee for Non-Officer Grants 1 ARTICLE 3. SHARES AVAILABLE FOR GRANTS 1 3.1 Basic Limitation 1 3.2 Shares Returned to Reserve 2 ARTICL |
|
| June 17, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Vanda Pharmaceuticals Inc. |
|
| June 17, 2022 |
As filed with the Securities and Exchange Commission on June 17, 2022 As filed with the Securities and Exchange Commission on June 17, 2022 Registration No. |
|
| June 16, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commissio |
|
| May 6, 2022 |
EXHIBIT 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS OF THE TYPE THAT VANDA TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH ?[***].? LICENSE AGREEMENT THIS LICENSE AGREEMENT (this ?Agreement?) dated as of January 13, 2022 (the ?Effective Date?) is entered into between Vanda Pharmaceuticals Inc., a D |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 5, 2022 |
Vanda Pharmaceuticals Reports First Quarter 2022 Financial Results Exhibit 99.1 Vanda Pharmaceuticals Reports First Quarter 2022 Financial Results WASHINGTON – May 5, 2022 /PRNewswire/ – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2022. “We are excited with our progress in improving patient access for HETLIOZ®, especially for Medicaid beneficiaries with Non-24 and SMS di |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commission |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| April 25, 2022 |
DEF 14A 1 vnda-20220421xdef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidentia |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 (February 28, 2022) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incor |
|
| February 24, 2022 |
EXHIBIT 10.29 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS OF THE TYPE THAT VANDA TREATS AS PRIVATE OR CONFIDENTIAL Manufacturing Agreement May 6, 2016 Table of Contents ARTICLE 1 2 INTERPRETATION 2 1.1 Definitions. 2 1.2 Currency 7 1.3 Sections and Headings. 7 1.4 Singular Terms. 7 1.5 Schedules 7 ARTICLE 2 8 PATHEON'S MANUFACTURING SER |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-34186 VANDA PHARMACEUTICALS INC. (Exact name of regist |
|
| February 24, 2022 |
EXHIBIT 10.12 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS OF THE TYPE THAT VANDA TREATS AS PRIVATE OR CONFIDENTIAL Manufacturing Agreement January 24, 2014 Table of Contents ARTICLE 1 1 INTERPRETATION 1 1.1 Definitions. 1 1.2 Currency. 6 1.3 Sections and Headings. 6 1.4 Singular Terms. 6 1.5 Schedules. 6 ARTICLE 2 7 PATHEON?S MANUFACTUR |
|
| February 24, 2022 |
EXHIBIT 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description is a summary that describes the securities of Vanda Pharmaceuticals Inc. (?Vanda,? the ?Company,? ?we,? ?us? and ?our?) that are registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended. The description does not purpor |
|
| February 23, 2022 |
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results ?Full year 2021 total revenues grew to $268.7 million, an 8% increase compared to 2020 ?Full year 2022 total revenues expected to be between $240 million and $280 million ?End of year 2022 Cash expected to be greater than $440 million WASHINGTON ? February 23, 2022 /PRNewswire/ ? Vanda Pharmaceuticals In |
|
| February 23, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commi |
|
| February 15, 2022 |
VNDA / Vanda Pharmaceuticals Inc. / ARMISTICE CAPITAL, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 15, 2022 |
Exhibit A AGREEMENT The undersigned agree that this Amendment No. 3 to Schedule 13G dated February 14, 2022 relating to the Common Stock, $0.001 par value per share, of Vanda Pharmaceuticals Inc. shall be filed on behalf of the undersigned. Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd Managing Member /s/ Steven Boyd Steven Boyd |
|
| February 14, 2022 |
VNDA / Vanda Pharmaceuticals Inc. / MACQUARIE GROUP LTD - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Vanda Pharmaceuticals Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 921659108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 10, 2022 |
VNDA / Vanda Pharmaceuticals Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Vanda Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 921659108 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| February 4, 2022 |
Vanda Pharmaceuticals Reports Results from the Phase III Study of Tradipitant in Gastroparesis Exhibit 99.1 Vanda Pharmaceuticals Reports Results from the Phase III Study of Tradipitant in Gastroparesis February 4, 2022 WASHINGTON, February 4, 2022 /PRNewswire/ ? Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced results from its Phase III clinical study, VP-VLY-686-3303, evaluating the efficacy and safety of tradipitant in treating the symptoms of gastroparesis. The study di |
|
| February 4, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2022 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commis |
|
| January 14, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2022 (January 13, 2022) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of inc |
|
| January 14, 2022 |
Vanda Pharmaceuticals Settles HETLIOZ Exhibit 99.1 Vanda Pharmaceuticals Settles HETLIOZ? Patent Litigation with MSN WASHINGTON, January 14, 2022 /PRNewswire/ ? Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it has entered into a License Agreement (the License Agreement) with MSN Pharmaceuticals Inc., MSN Laboratories Private Limited (together MSN) and Impax Laboratories LLC (Impax) to resolve Vanda?s patent litigat |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 3, 2021 |
Vanda Pharmaceuticals Reports Third Quarter 2021 Financial Results Exhibit 99.1 Vanda Pharmaceuticals Reports Third Quarter 2021 Financial Results ?Q3 2021 total revenues were $70.1 million, a 16% increase compared to Q3 2020 ?Total revenues for the first nine months of 2021 were $200.7 million, an 11% increase compared to the first nine months of 2020 ?Enrollment of the Phase III clinical study of tradipitant in gastroparesis is complete and results are expected |
|
| November 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commis |
|
| October 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2021 (October 6, 2021) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incor |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| July 28, 2021 |
Vanda Pharmaceuticals Reports Second Quarter 2021 Financial Results Exhibit 99.1 Vanda Pharmaceuticals Reports Second Quarter 2021 Financial Results ?Q2 2021 total revenues were $67.9 million, a 9% increase compared to Q2 2020 ?Total revenues for the first six months of 2021 were $130.6 million, a 9% increase compared to the first six months of 2020 ?Results from Phase III clinical study of tradipitant in gastroparesis are expected by the end of 2021 WASHINGTON ? |
|
| July 28, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2021 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commissio |
|
| June 10, 2021 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commissio |
|
| June 10, 2021 |
Exhibit 10.1 VANDA PHARMACEUTICALS INC. 2016 EQUITY INCENTIVE PLAN (AMENDED AND RESTATED EFFECTIVE AS OF JUNE 11, 2020) TABLE OF CONTENTS Page ARTICLE 1. INTRODUCTION 1 ARTICLE 2. ADMINISTRATION 1 2.1 Committee Composition 1 2.2 Committee Responsibilities 1 2.3 Committee for Non-Officer Grants 1 ARTICLE 3. SHARES AVAILABLE FOR GRANTS 1 3.1 Basic Limitation 1 3.2 Shares Returned to Reserve 2 ARTICL |
|
| June 10, 2021 |
As filed with the Securities and Exchange Commission on June 10, 2021 As filed with the Securities and Exchange Commission on June 10, 2021 Registration No. |
|
| May 6, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commission |
|
| May 5, 2021 |
Vanda Pharmaceuticals Reports First Quarter 2021 Financial Results Exhibit 99.1 Vanda Pharmaceuticals Reports First Quarter 2021 Financial Results ?Q1 2021 total revenues were $62.7 million, an 8% increase compared to Q1 2020 ?The Phase III clinical study of tradipitant in gastroparesis is expected to complete enrollment in the second quarter of 2021 ?A Phase III clinical study for HETLIOZ? in delayed sleep phase disorder (DSPD) was initiated in the first quarter |
|
| April 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| April 22, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permi |
|
| February 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 (February 24, 2021) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-341 |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Vanda Pharmaceuticals Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 921659108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 11, 2021 |
Exhibit 21.1 Vanda Pharmaceuticals Inc. List of Subsidiaries Name of Wholly-Owned Subsidiary Jurisdiction of Organization Name under which the subsidiary conducts business Vanda Pharmaceuticals Limited United Kingdom Vanda Pharmaceuticals Limited Vanda Pharmaceuticals GmbH Switzerland Vanda Pharmaceuticals GmbH Vanda Pharmaceuticals Germany GmbH Germany Vanda Pharmaceuticals Germany GmbH Vanda Pha |
|
| February 11, 2021 |
EXHIBIT 10.41 EXECUTION COPY AMENDMENT NO. 6 TO LEASE THIS AMENDMENT NO. 6 TO LEASE (“Amendment No. 6”) is made as of the 7th day of May, 2020 (“Effective Date”), by and between SQUARE 54 OFFICE OWNER LLC, a Delaware limited liability company (“Landlord”), and VANDA PHARMACEUTICALS INC., a Delaware corporation (“Tenant”). WITNESSETH: WHEREAS, by Lease dated as of July 25, 2011 (the “Initial Lease” |
|
| February 11, 2021 |
EXHIBIT 10.40 EXECUTION COPY AMENDMENT NO. 5 TO LEASE THIS AMENDMENT NO. 5 TO LEASE (“Amendment No. 5”) is made as of the 11th day of April, 2019 (“Effective Date”), by and between SQUARE 54 OFFICE OWNER LLC, a Delaware limited liability company (“Landlord”), and VANDA PHARMACEUTICALS INC., a Delaware corporation (“Tenant”). WITNESSETH: WHEREAS, by Lease dated as of July 25, 2011 (the “Initial Lea |
|
| February 11, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-34186 VANDA PHARMACEUTICALS INC. (Exact name of regist |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Vanda Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 921659108 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| February 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2021 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) 001-34186 Delaware 03-0491827 (Commission File No.) (State or other jurisdiction of |
|
| February 10, 2021 |
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results Exhibit 99.1 Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results •Q4 2020 total revenues grew to $67.7 million, an 11% increase compared to Q4 2019 •Full year 2020 total revenues grew to $248.2 million, a 9% increase compared to 2019 •Full year 2021 total revenues expected to be between $270 million and $300 million, an increase of approximately 15% compared to 2020 • |
|
| December 2, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2020 (December 1, 2020) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34186 |
|
| December 2, 2020 |
EX-99.1 Exhibit 99.1 FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome WASHINGTON, December 1, 2020 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved HETLIOZ® (tasimelteon) capsule and liquid formulations for the treatment of adults and children |
|
| October 29, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| October 28, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2020 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) 001-34186 Delaware 03-0491827 (Commission File No.) (State or other jurisdiction of |
|
| October 28, 2020 |
Vanda Pharmaceuticals Reports Third Quarter 2020 Financial Results Exhibit 99.1 Vanda Pharmaceuticals Reports Third Quarter 2020 Financial Results •Q3 2020 Total net product sales of $60.3 million, a 1% increase compared to Q3 2019 •Total net product sales for the first nine months of 2020 grew to $180.5 million, a 9% increase compared to the same period in 2019 •The HETLIOZ® Smith-Magenis Syndrome marketing authorization applications accepted by the FDA for prio |
|
| August 18, 2020 |
EX-99.1 Exhibit 99.1 Vanda Pharmaceuticals’ Interim Analysis from ODYSSEY Study Shows Tradipitant may Accelerate Clinical Improvement in Patients with COVID-19 Pneumonia WASHINGTON, August 18, 2020 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today reported that interim analysis showed tradipitant may accelerate clinical improvement in SARS-CoV-2 (COVID-19) pneumonia in the ODY |
|
| August 18, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2020 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34186 03-0491827 (Commiss |
|
| August 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 5, 2020 |
Vanda Pharmaceuticals Reports Second Quarter 2020 Financial Results EX-99.1 2 vnda8-k8520exhibit991.htm EX-99.1 Exhibit 99.1 Vanda Pharmaceuticals Reports Second Quarter 2020 Financial Results •Q2 2020 Total net product sales reached a new record of $62.2 million, a 7% increase as compared to Q1 2020 •Q2 2020 HETLIOZ® net product sales reached a new record of $41.6 million, an 18% increase as compared to Q1 2020 •The HETLIOZ® SMS marketing authorization applicatio |
|
| August 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2020 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) 001-34186 Delaware 03-0491827 (Commission File No.) (State or other jurisdiction of in |
|
| July 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2020 (July 27, 2020) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34186 03-04 |
|
| July 29, 2020 |
EX-10.1 EXHIBIT 10.1 VANDA PHARMACEUTICALS INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) by and between KEVIN MORAN (the “Executive”) and VANDA PHARMACEUTICALS INC., a Delaware corporation (the “Company”) was originally entered into as of August 6, 2010 and was amended and restated as of May 5, 2020. This Agreement is hereby further amended and restate |
|
| June 11, 2020 |
S-8 As filed with the Securities and Exchange Commission on June 11, 2020 Registration No. |
|
| June 11, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2020 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware 001-34186 03-0491827 (State or other jurisdiction of incorporation) (Commissio |
|
| June 11, 2020 |
EX-10.1 Exhibit 10.1 VANDA PHARMACEUTICALS INC. 2016 EQUITY INCENTIVE PLAN (AMENDED AND RESTATED EFFECTIVE AS OF JUNE 11, 2020) TABLE OF CONTENTS Page ARTICLE 1. INTRODUCTION 1 ARTICLE 2. ADMINISTRATION 1 2.1 Committee Composition 1 2.2 Committee Responsibilities 2 2.3 Committee for Non-Officer Grants 2 ARTICLE 3. SHARES AVAILABLE FOR GRANTS 2 3.1 Basic Limitation 2 3.2 Shares Returned to Reserve |
|
| May 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| May 26, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2020 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34186 03-0491827 (Commission |
|
| May 26, 2020 |
Vanda Pharmaceuticals Announces Virtual 2020 Stockholder Meeting EX-99.1 2 vanda-form8xk5262020pr.htm EX-99.1 Vanda Pharmaceuticals Announces Virtual 2020 Stockholder Meeting WASHINGTON – May 26, 2020 /PRNewswire/ – Vanda Pharmaceuticals Inc. (“Vanda”) (Nasdaq: VNDA), announced today that Vanda will hold its 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”) in a virtual-only format due to public health concerns related to the COVID-19 pandemic and |
|
| May 13, 2020 |
EX-99.1 Exhibit 99.1 Vanda Pharmaceuticals Announces Agreement with FDA on Resubmission of the Application for HETLIOZ® for the Treatment of Patients with Smith-Magenis Syndrome WASHINGTON, May 13, 2020 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that following the completion of a Type A Meeting with the U.S. Food and Drug Administration (FDA) on May 8, 2020, i |
|
| May 13, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2020 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34186 03-0491827 (Commission |
|
| May 7, 2020 |
EXHIBIT 10.42 VANDA PHARMACEUTICALS INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) by and between KEVIN MORAN (the “Executive”) and VANDA PHARMACEUTICALS INC., a Delaware corporation (the “Company”) was originally entered into as of August 6, 2010. This Agreement is hereby amended and restated as of May 5, 2020. 1.Duties and Scope of Employment. (a) Pos |
|
| May 7, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2020 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34186 03-0491827 (Commission |
|
| May 6, 2020 |
Vanda Pharmaceuticals Reports First Quarter 2020 Financial Results EX-99.1 2 d849498dex991.htm EX-99.1 Exhibit 99.1 Vanda Pharmaceuticals Reports First Quarter 2020 Financial Results • Q1 2020 Total net product sales of $58.0 million, a 22% increase year over year • Advancing the Commercial and Development Pipeline; Initiating Studies for COVID-19 WASHINGTON – May 6, 2020 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operationa |
|
| April 22, 2020 |
VNDA / Vanda Pharmaceuticals, Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| April 22, 2020 |
VNDA / Vanda Pharmaceuticals, Inc. DEF 14A - - DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permi |
|
| March 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2020 (March 12, 2020) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34186 03- |
|
| March 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2020 (February 26, 2020) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34186 0 |
|
| February 26, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-34186 VANDA PHARMACEUTICALS INC. (Exact name of regist |
|
| February 26, 2020 |
EX-99.1 2 d892669dex991.htm EX-99.1 Exhibit 99.1 Vanda Reports results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis • Tradipitant antipruritic effects not seen in moderate or severe Atopic Dermatitis and the study did not meet its primary endpoint • Tradipitant significantly improved severe itch and nighttime sleep in patients with mild Atopic Dermatitis • |
|
| February 26, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2020 (February 25, 2020) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-341 |
|
| February 25, 2020 |
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results EX-99.1 2 d892944dex991.htm EX-99.1 Exhibit 99.1 Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results • Full year 2019 total revenues grew to $227.2 million, an 18% increase compared to 2018 • Full year 2020 total revenues expected to be between $240 million and $260 million • Results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatiti |
|
| February 25, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2020 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34186 03-0491827 (Commi |
|
| February 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2020 (February 18, 2020) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-341 |
|
| February 19, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2020 (February 14, 2020) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-341 |
|
| February 19, 2020 |
Vanda Pharmaceuticals Appoints Stephen Ray Mitchell to Board of Directors EX-99.1 2 d885396dex991.htm EX-99.1 Exhibit 99.1 Vanda Pharmaceuticals Appoints Stephen Ray Mitchell to Board of Directors WASHINGTON, February 19, 2020 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announces the appointment of Stephen Ray Mitchell, M.D. to its Board of Directors. “Ray is a highly respected leader in academic medicine and globally recognized expert in Pediatrics |
|
| February 14, 2020 |
VNDA / Vanda Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* VANDA PHARMACEUTICALS INC (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 921659108 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 13, 2020 |
VNDA / Vanda Pharmaceuticals, Inc. / MACQUARIE GROUP LTD - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Vanda Pharmaceuticals Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 921659108 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 12, 2020 |
VNDA / Vanda Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Vanda Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 921659108 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| February 3, 2020 |
Vanda Pharmaceuticals Comments on Court Ruling EX-99.1 2 d821524dex991.htm EX-99.1 Exhibit 99.1 Vanda Pharmaceuticals Comments on Court Ruling WASHINGTON – Jan. 31, 2020 /PRNewswire/ – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) makes the following statement regarding U.S. District Court case 19-cv-30; U.S. Food and Drug Administration (FDA) v. Vanda, in which the U.S. District Court for the District of Columbia ruled in favor of the FDA |
|
| February 3, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2020 (January 31, 2020) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34186 |
|
| January 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2020 (January 15, 2020) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34186 |
|
| January 13, 2020 |
Vanda Pharmaceuticals Wins Key U.S. Supreme Court Patent Ruling on Fanapt EX-99.1 2 d864410dex991.htm EX-99.1 Exhibit 99.1 Vanda Pharmaceuticals Wins Key U.S. Supreme Court Patent Ruling on Fanapt® WASHINGTON – January 13, 2020 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that the U.S. Supreme Court has denied the petition for a writ of certiorari filed by West-Ward Pharmaceuticals (West-Ward), a subsidiary of Hikma Pharmaceuticals, relating to Va |
|
| January 13, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2020 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34186 03-0491827 (Commis |
|
| November 7, 2019 |
EXHIBIT 10.40 VANDA PHARMACEUTICALS INC. EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of July 3, 2019, by and between Aranthan “AJ” Jones II (the “Executive”) and VANDA PHARMACEUTICALS INC., a Delaware corporation (the “Company”). 1. Duties and Scope of Employment. (a)Position. During his employment under this Agreement (“Employment”), the Company agrees to |
|
| November 7, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 7, 2019 |
EX-10.41 3 vndaex10410930201910q.htm EXHIBIT 10.41 EXHIBIT 10.41 VANDA PHARMACEUTICALS INC. EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of August 5, 2019, by and between Joakim Wijkstrom (the “Executive”) and VANDA PHARMACEUTICALS INC., a Delaware corporation (the “Company”). 1. Duties and Scope of Employment. (a) Position. During his employment under this |
|
| November 6, 2019 |
EX-99.1 Exhibit 99.1 Vanda Pharmaceuticals Reports Third Quarter 2019 Financial Results • Q3 2019 Total net product sales of $59.5 million, a 21% increase year over year • Vanda reiterates full year 2019 revenue guidance of $215 to $225 million and expects results in the upper half of the range WASHINGTON – November 6, 2019 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financ |
|
| November 6, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2019 VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34186 03-0491827 (Commis |
|
| October 28, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2019 (October 22, 2019) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34186 |
|
| October 28, 2019 |
Vanda Pharmaceuticals Appoints Anne Sempowski Ward to Board of Directors EX-99.1 2 d825479dex991.htm EX-99.1 Exhibit 99.1 Vanda Pharmaceuticals Appoints Anne Sempowski Ward to Board of Directors WASHINGTON, October 28, 2019 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Anne Sempowski Ward has joined the company’s Board of Directors, effective October 28, 2019. Following Ms. Ward’s appointment, Vanda’s Board of Directors is now co |
|
| August 19, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2019 (August 16, 2019) VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-34186 0 |
|
| August 19, 2019 |
Vanda Pharmaceuticals FDA Update for HETLIOZ® in the Treatment of Jet Lag Disorder EX-99.1 2 d782062dex991.htm EX-99.1 Exhibit 99.1 Vanda Pharmaceuticals FDA Update for HETLIOZ® in the Treatment of Jet Lag Disorder WASHINGTON – August 19, 2019 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that on August 16 2019, it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) as part of its ongoing review of Vanda’s supplemental |
